Lumexa Imaging Announces Pricing of Initial Public Offering

Rhea-AI Summary

Lumexa Imaging (NASDAQ: LMRI) priced its initial public offering of 25,000,000 shares of common stock at $18.50 per share, with a 30‑day underwriter option for up to 3,750,000 additional shares.

The Common Stock is expected to begin trading on the Nasdaq Global Select Market under the symbol LMRI on December 11, 2025, and the offering is expected to close on December 12, 2025, subject to customary closing conditions. The registration statement on Form S‑1 was declared effective by the SEC on December 10, 2025.

Positive

• Offer size: 25,000,000 shares priced at $18.50
• Overallotment: 30‑day option for 3,750,000 additional shares
• Listing: Expected Nasdaq Global Select listing under LMRI on Dec 11, 2025
• Regulatory: S‑1 declared effective by the SEC on Dec 10, 2025

Negative

• None.

Insights

Capital Markets Analyst

Lumexa priced a material IPO, signaling capital access and immediate public-market liquidity starting Dec. 11, 2025.

Lumexa Imaging set an offering of 25,000,000 shares at $18.50 per share with a 30‑day 15% overallotment option for 3,750,000 additional shares. The shares are expected to begin trading on Nasdaq Global Select under the symbol "LMRI" on Dec. 11, 2025 and the offering is expected to close on Dec. 12, 2025. The syndicate includes major underwriters, which supports distribution capacity.

The business impact flows from newly raised public capital and the transition to a reporting company. Key dependencies are satisfaction of customary closing conditions and final prospectus availability. Monitor the actual closing on Dec. 12, 2025, the use of proceeds disclosed in the final prospectus, and any lock‑up terms once filed; those items determine near‑term dilution and capital allocation.

RALEIGH, N.C., Dec. 10, 2025 /PRNewswire/ -- Lumexa Imaging Holdings, Inc. ("Lumexa Imaging") announced today the pricing of its initial public offering of 25,000,000 shares of its common stock, par value $0.001 per share (the "Common Stock"), at a price to the public of $18.50 per share of Common Stock. In connection with the offering, Lumexa Imaging has granted the underwriters a 30-day option to purchase up to an additional 3,750,000 shares of its Common Stock. The Common Stock is expected to begin trading on the Nasdaq Global Select Market under the symbol "LMRI" on December 11, 2025, and the offering is expected to close on December 12, 2025, subject to the satisfaction of customary closing conditions.

Barclays, J.P. Morgan and Jefferies are acting as joint lead book-running managers. Deutsche Bank Securities and Wells Fargo Securities are acting as book-running managers. Leerink Partners, William Blair, Capital One Securities, Fifth Third Securities and Raymond James are acting as bookrunners. PNC Capital Markets LLC, Academy Securities, Loop Capital Markets and R. Seelaus & Co., LLC are acting as co-managers.

The offering of Lumexa Imaging's Common Stock is being made only by means of a prospectus. Copies of the final prospectus relating to the offering, when available, may be obtained for free by visiting EDGAR on the U.S. Securities and Exchange Commission (the "SEC") website at www.sec.gov. Alternatively, copies of the final prospectus, when available, may be obtained from: Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (888) 603-5847, or by email at barclaysprospectus@broadridge.com; J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717 or by email: prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com; or Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388 or by email at prospectus_department@jefferies.com.

A registration statement on Form S-1 relating to the Common Stock was declared effective by the SEC on December 10, 2025. This press release does not constitute an offer to sell or the solicitation of an offer to buy Common Stock, and shall not constitute an offer, solicitation or sale in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that state or jurisdiction.

ABOUT LUMEXA IMAGING

Lumexa Imaging is a nationwide provider of diagnostic imaging services. As of September 30, 2025, we and our affiliates operated the second largest outpatient imaging center footprint in the United States. It spans 184 centers across 13 states and includes eight joint venture partnerships with health systems.

MEDIA CONTACT

Melissa Weston
corpcomms@lumexaimaging.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/lumexa-imaging-announces-pricing-of-initial-public-offering-302638582.html

SOURCE Lumexa Imaging

FAQ

How many shares did Lumexa Imaging (LMRI) offer in its IPO and at what price?

Lumexa Imaging offered 25,000,000 shares at $18.50 per share.

What is the Nasdaq ticker and expected first trading date for Lumexa Imaging (LMRI)?

The Common Stock is expected to trade under LMRI on the Nasdaq Global Select Market starting December 11, 2025.

Did Lumexa Imaging (LMRI) grant an overallotment option in the IPO?

Yes, the company granted underwriters a 30‑day option to purchase up to 3,750,000 additional shares.

When is the Lumexa Imaging (LMRI) IPO expected to close?

The offering is expected to close on December 12, 2025, subject to customary closing conditions.

Has the SEC declared Lumexa Imaging's registration statement effective for the IPO (LMRI)?

Yes, the Form S‑1 registration statement was declared effective by the SEC on December 10, 2025.